Kidney Disease Clinical Trial
Official title:
Prediction Equations for Glomerular Filtration Rate in Children Based on Serum Cystatin C and Body Cell Mass
The purpose of this study is to assess serum cystatin C as a marker of kidney function
(glomerular filtration rate, GFR) in children aged 2-14. The individual production rate and
possible extra renal elimination of cystatin C based on body composition data is included to
develop new algorithms to estimate GFR.
Furthermore, day-to-day variation on serum cystatin C is investigated.
Today, children's kidney function (glomerular filtration rate, GFR) can be monitored by two
methods:
1. indirectly by serum creatinine, or
2. directly by injection of a radioactive substance followed by several blood samples.
The first method is inaccurate with many drawbacks, whereas the latter is precise but
time-consuming and unpleasant for the child. Therefore, there is a need for a new method for
investigating GFR in children.
Serum cystatin C is a small protein that is produced with a constant rate in all nucleated
cells in the body. It meets many of the characteristics of an ideal marker of GFR because of
the way it is excreted in the kidneys. However, earlier studies have not proven serum
cystatin C to be convincingly better than serum creatinine. Why? If there is considerable
extra renal elimination, serum cystatin C alone isn't enough to estimate GFR. Therefore, the
individual production rate and possible extra renal elimination of cystatin C are included
in this study. To assess these factors, the children are submitted to bioelectrical
impedance spectroscopy (BIS) to estimate their body composition, including body cell mass as
cystatin C is produced in all nucleated cells. To validate the BIS data, dual energy x-ray
absorptiometry (DEXA) will be conducted on 100 of the included children.
Based on serum cystatin C and the individual, age-corrected extra renal elimination rate of
cystatin C, new algorithms to calculate GFR can be developed.
Furthermore, day-to-day variation in serum cystatin C and BIS data, which is expected to be
low, is investigated in 100 of the included children.
Hypotheses:
1. Day-to-day variation on serum cystatin C is low.
2. Serum cystatin C raises parallel to falling GFR with time, which means that serum
cystatin C can be used to monitor changes in kidney function in each patient.
3. Based on body composition, regression analysis and serum cystatin C values, GFR can be
estimated in children aged 2-14.
4. GFR calculated as stated above is a more precise measurement of kidney function and
changes in kidney function than GFR estimated from serum creatinine.
5. Data of body composition estimated by BIS do not deviate from data estimated by DEXA
6. Day-to-day variation in data for body composition measured by BIS is low.
The project includes 200 children aged 2-14 who are referred for routine examination of GFR
in two Departments of Nuclear Medicine.
;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02369354 -
Transplant Social Worker Support for Live Kidney Donation in African Americans
|
N/A | |
| Not yet recruiting |
NCT02225782 -
Trial to Compare 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring Hemodialysis Catheter Function
|
Phase 4 | |
| Completed |
NCT00499187 -
Fanconi Syndrome Due to ARVs in HIV-Infected Persons
|
Phase 4 | |
| Completed |
NCT00379899 -
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
|
Phase 4 | |
| Withdrawn |
NCT00585429 -
Evaluation of Kidney Disease in Liver Transplant Recipients
|
N/A | |
| Completed |
NCT00183248 -
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT00001835 -
Oxaliplatin in Cancer Patients With Impaired Kidney Function
|
Phase 1 | |
| Completed |
NCT01331941 -
A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function
|
Phase 1 | |
| Terminated |
NCT00436748 -
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
|
Phase 3 | |
| Completed |
NCT01467466 -
Prevention of Serious Adverse Events Following Angiography
|
Phase 3 | |
| Completed |
NCT01235936 -
Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia
|
Phase 2 | |
| Completed |
NCT01947829 -
Interdialytic Kt/V Variability Measurement With Adimea (IVP STUDY)
|
N/A | |
| Completed |
NCT01974999 -
A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study
|
||
| Recruiting |
NCT01240564 -
The Nephrotic Syndrome Study Network (NEPTUNE)
|
N/A | |
| Active, not recruiting |
NCT01228903 -
Uric Acid and the Endothelium is CKD
|
N/A | |
| Completed |
NCT00734357 -
Comparative Investigation of Intravenously Administered Omnipaque and Isovue: Effects on Serum Creatinine Concentration in Outpatients
|
N/A | |
| Completed |
NCT00781417 -
Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease
|
N/A | |
| Completed |
NCT00185159 -
Olmesartan Medoxomil in Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT00093977 -
Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease
|
Phase 3 | |
| Completed |
NCT00094484 -
Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis
|
Phase 3 |